Cargando…
Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives
Several elements highlight the importance of the mechanistic target of rapamycin (mTOR) in the biology of renal cell carcinoma (RCC). mTOR signaling pathway is indeed frequently activated in RCC, inducing cancer cell proliferation and survival. In addition, mTOR promotes tumor angiogenesis and regul...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005589/ https://www.ncbi.nlm.nih.gov/pubmed/33791295 http://dx.doi.org/10.3389/fcell.2021.636037 |
_version_ | 1783672140640288768 |
---|---|
author | Faes, Seraina Demartines, Nicolas Dormond, Olivier |
author_facet | Faes, Seraina Demartines, Nicolas Dormond, Olivier |
author_sort | Faes, Seraina |
collection | PubMed |
description | Several elements highlight the importance of the mechanistic target of rapamycin (mTOR) in the biology of renal cell carcinoma (RCC). mTOR signaling pathway is indeed frequently activated in RCC, inducing cancer cell proliferation and survival. In addition, mTOR promotes tumor angiogenesis and regulates the expression of hypoxia-inducible factors that play an important role in a subset of RCC. Despite mTOR protumorigenic effects, mTOR inhibitors have failed to provide long-lasting anticancer benefits in RCC patients, highlighting the need to readdress their role in the treatment of RCC. This review aims to present the rationale and limitations of targeting mTOR in RCC. Future roles of mTOR inhibitors in the treatment of RCC are also discussed, in particular in the context of immunotherapies. |
format | Online Article Text |
id | pubmed-8005589 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-80055892021-03-30 Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives Faes, Seraina Demartines, Nicolas Dormond, Olivier Front Cell Dev Biol Cell and Developmental Biology Several elements highlight the importance of the mechanistic target of rapamycin (mTOR) in the biology of renal cell carcinoma (RCC). mTOR signaling pathway is indeed frequently activated in RCC, inducing cancer cell proliferation and survival. In addition, mTOR promotes tumor angiogenesis and regulates the expression of hypoxia-inducible factors that play an important role in a subset of RCC. Despite mTOR protumorigenic effects, mTOR inhibitors have failed to provide long-lasting anticancer benefits in RCC patients, highlighting the need to readdress their role in the treatment of RCC. This review aims to present the rationale and limitations of targeting mTOR in RCC. Future roles of mTOR inhibitors in the treatment of RCC are also discussed, in particular in the context of immunotherapies. Frontiers Media S.A. 2021-03-15 /pmc/articles/PMC8005589/ /pubmed/33791295 http://dx.doi.org/10.3389/fcell.2021.636037 Text en Copyright © 2021 Faes, Demartines and Dormond. http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Cell and Developmental Biology Faes, Seraina Demartines, Nicolas Dormond, Olivier Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives |
title | Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives |
title_full | Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives |
title_fullStr | Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives |
title_full_unstemmed | Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives |
title_short | Mechanistic Target of Rapamycin Inhibitors in Renal Cell Carcinoma: Potential, Limitations, and Perspectives |
title_sort | mechanistic target of rapamycin inhibitors in renal cell carcinoma: potential, limitations, and perspectives |
topic | Cell and Developmental Biology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8005589/ https://www.ncbi.nlm.nih.gov/pubmed/33791295 http://dx.doi.org/10.3389/fcell.2021.636037 |
work_keys_str_mv | AT faesseraina mechanistictargetofrapamycininhibitorsinrenalcellcarcinomapotentiallimitationsandperspectives AT demartinesnicolas mechanistictargetofrapamycininhibitorsinrenalcellcarcinomapotentiallimitationsandperspectives AT dormondolivier mechanistictargetofrapamycininhibitorsinrenalcellcarcinomapotentiallimitationsandperspectives |